Gene amplification of chromatin remodeling factor SMARCC2 and low protein expression of ACTL6A are unfavorable factors in ovarian high-grade serous carcinoma

NAOMI MAGARIFUCHI¹ ², TAKESHI IWASAKI¹, YOSHIHIRO KATAYAMA¹ ², TAKUMI TOMONAGA¹, MIYA NAKASHIMA¹ ², FUMIYA NARUTOMI¹, KIYOKO KATO² and YOSHINAO ODA¹

Departments of ¹Anatomic Pathology and ²Gynecology and Obstetrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Fukuoka 812-8582, Japan

Received October 4, 2023; Accepted January 23, 2024

DOI: 10.3892/ol.2024.14329

Correspondence to: Professor Yoshinao Oda, Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi, Fukuoka, Fukuoka 812-8582, Japan
E-mail: oda.yoshinao.389@m.kyushu-u.ac.jp

Abstract. Ovarian high-grade serous carcinoma (OHGSC) is the most common type of ovarian cancer worldwide. Genome sequencing has identified mutations in chromatin remodeling factors (CRFs) in gynecological cancer, such as clear cell carcinoma, endometrioid carcinoma and endometrial serous carcinoma. However, to the best of our knowledge, the association between CRFs and OHGSC remains unexplored. The present study aimed to investigate the clinicopathological and molecular characteristics of CRF dysfunction in OHGSC. CRF alterations were analyzed through numerous methods, including the analysis of public next-generation sequencing (NGS) data from 585 ovarian serous carcinoma cases from The Cancer Genome Atlas (TCGA), immunohistochemistry (IHC), and DNA copy number assays, which were performed on 203 surgically resected OHGSC samples. In the public NGS dataset, the most frequent genetic alteration was actin-like protein 6A (ACTL6A) amplification at 19.5%. Switch/sucrose non-fermentable related, matrix associated, actin dependent regulator of chromatin subfamily c member 2 (SMARCC2) amplification (3.1%) was associated with significantly decreased overall survival (OS). In addition, chromodomain-helicase-DNA-binding protein 4 (CHD4) amplification (5.7%) exhibited unfavorable outcome trends, although not statistically significant. IHC revealed the protein expression loss of ARID1A (2.5%), SMARCA2 (2.5%) and SMARCA4 (3.9%). The protein expression levels of ACTL6A, SMARCC2 and CHD4 were evaluated using H-score. Patients with low protein expression levels of ACTL6A showed a significantly decreased OS. Copy number gain or gene amplification was demonstrated in ACTL6A (66.2%) and SMARCC2 (33.5%), while shallow deletion or deep deletion was demonstrated in CHD4 (70.7%). However, there was no statistically significant difference in protein levels of these CRFs, between the different copy number alterations (CNAs). Overall, OHGSC exhibited CNAs and protein loss, indicating possible gene alterations in CRFs. Moreover, there was a significant association between the protein expression levels of ACTL6A and poor prognosis. Based on these findings, it is suggested that CRFs could serve as prognostic markers for OHGSC.

Introduction

Ovarian high-grade serous carcinoma (OHGSC) is the most common type of epithelial ovarian cancer, accounting for 60% of all ovarian malignancies and 70% of ovarian cancer-related deaths in the United States (1,2). Survival in OHGSC is influenced by numerous factors, such as age, cancer stage and the size of residual tumor after cytoreductive surgery (3,4). Epigenetic dysregulation has been recognized as a significant factor in cancer development, progression and chemoresistance (5). These alterations involve abnormal DNA methylation patterns, disrupted histone posttranslational modifications, and changes in chromatin composition and/or organization (6). Chromatin remodeling factors (CRFs) serve a vital role in modifying chromatin structure, regulating the accessibility of DNA to
transcription factors and machinery and thereby dynamically influencing gene expression (7). Genome sequencing studies have revealed a high prevalence of CRF mutations across numerous cancer types (8). In the context of gynecological cancer, AT-rich interaction domain 1A (ARID1A) mutations have been identified in 35-46% of ovarian clear cell carcinoma, 30-63% of ovarian endometrioid carcinoma, 6% of endometrial serous carcinoma and 14% of carcinosarcoma cases (9-11). Chromodomain-helicase-DNA-binding protein 4 (CHD4) somatic mutations have been detected in 17% of endometrial serous carcinoma (10), while switch/sucrose non-fermentable (SWI/SNF) related, matrix associated, actin dependent regulator of chromatin (SMARC) subfamily a member 4 (SMARCA4) germline and somatic mutations have been found in 69% of cases of small cell carcinoma of the ovary, hypercalcemic type (12). A previous study reported that CHD4 mRNA expression is significantly higher in platinum-resistant cases compared with in platinum-sensitive cases of OHGSC and ovarian clear cell carcinoma (13). Despite these findings, to the best of our knowledge, there has not been a comprehensive and large-scale investigation exploring the association between CRFs and OHGSC.

In the present study, a comprehensive analysis of OHGSC cases from histological, immunohistochemical and genetic perspectives was conducted to elucidate the role of CRF dysfunction in OHGSC.

Materials and methods

Public data analysis. The cBioPortal (http://www.cbio-portal.org/) (14,15) was used to retrieve public whole exome sequencing data and mRNA sequencing data for ovarian serous carcinoma. Initially, ‘Ovary/Fallopian Tube’ was selected in the ‘Select Studies for Visualization & Analysis’ and the Ovarian Serous Cystadenocarcinoma dataset [The Cancer Genome Atlas (TCGA), PanCancer Atlas; https://www.cancer.gov/tcga] was chosen. This dataset from TCGA contains whole exome sequencing data from 585 cases, and mRNA sequencing data from 300 cases of ovarian serous carcinoma. Genomic alterations, mRNA expression and survival data were analyzed via the cBioPortal website by submitting a query regarding CRFs, including ARID1A, AT-rich interaction domain 1B, actin-like protein 6A (ACTL6A), SMARCA1, SMARCA2, SMARCA4, SMARCA5, SMARC subfamily b member 1 (SMARCB1), SMARC subfamily c member 1 (SMARCC1), SMARCC2, SMARC subfamily d member 1, SMARC subfamily e member 1, helicase-like transcription factor, chromodomains-helicase-DNA-binding protein 1 (CHD1), CHD2, CHD3, CHD4, CHD5, inositol-requiring 8 and bromodomain-containing protein 9. The genetic alterations in the ‘OncoPrint’ module were analyzed and mRNA expression levels in the ‘mRNA’ module of ‘Comparison/Survival’ were displayed.

Moreover, the association of individual CRF genes with prognosis was compared, and patients within the dataset were categorized into two groups: One with CRF gene amplification, and the other without genetic alteration of CRFs. The prognostic value of individual mRNA expression levels of CRF genes in the two groups was compared using median normalized RNA-seq by expectation maximization values (cut off values: ACTL6A, 2,117; SMARCC2, 3,607; CHD4, 6,891). Survival curves were constructed using the Kaplan-Meier method, and the log-rank test was performed using the ‘Survival’ module of ‘Comparison/Survival’ on cBioportal to analyze overall survival (OS).

Case selection and clinicopathological characteristics. The present retrospective study adhered to the principles outlined in The Declaration of Helsinki. This study was approved by the Ethics Committee of Kyushu University (Fukuoka, Japan; approval nos. 21120-01, 21037-02 and 23005-00). The case records of the Department of Anatomic Pathology, Kyushu University from 1988-2020 were accessed to identify cases of ovarian serous carcinoma with available clinical data and formalin-fixed and paraffin-embedded (FFPE) blocks of ovarian tissue. This search yielded 318 cases of surgically resected ovarian serous carcinoma. Cases other than primary ovarian cancer (12 cases involving fallopian tube and 9 cases involving peritoneal cancer) were excluded, as were cases where neoadjuvant chemotherapy had been administered (91 cases). All cases were independently reviewed by two pathologists (NM and TI). The typical histological structure of OHGSC was confirmed, including papillary or solid proliferation, severe nuclear atypia and frequent mitotic figures, in accordance with the World Health Organization Classification of Female Genital Tumors (16). Additionally, three cases diagnosed with low-grade serous carcinoma were excluded. Ultimately, this analysis included 203 cases of OHGSC. All tumor samples were FFPE. For both immunohistochemistry (IHC) and copy number assays, one representative FFPE block was used for each case. Clinical data, including age, International Federation of Gynecology and Obstetrics (FIGO) 2014 stage (17), presence of metastases, adjuvant therapy and prognosis, were obtained from medical records. Furthermore, one normal skeletal muscle tissue was collected from the Department of Anatomic Pathology, Kyushu University as the control for copy number assays.

Immunohistochemical staining. The primary antibodies used for IHC staining are listed in Table S1. Staining conditions were optimized by testing numerous approaches. FFPE tissue was cut into 3 µm sections for further processing. The paraffin-embedded sections were deparaffinized in xylene and rehydrated in ethanol series (99, 90 and 80%). Antigen retrieval was performed by boiling the slides at 98 or 110°C in Target Retrieval Solution (pH 9.0; Dako; Agilent Technologies, Inc) for ARID1A, SMARCA4, SMARCB1, SMARCC2, tri-methylation of lysine 27 of histone H3 (H3K27me3) and p53 staining, while 10 mM sodium citrate (pH 6.0) was used for SMARCA2, CHD4 and ACTL6A. Subsequently, 3% hydrogen peroxide was used for blocking endogenous peroxidase activity at room temperature for 5 min and PBS was used for washing. Sections were then incubated with the primary antibodies at room temperature for 90 min (CHD4, ACTL6A, H3K27me3 and p53) or at 4°C overnight (ARID1A, SMARCA2, SMARCA4, SMARCB1 and SMARCC2). The EnVision-kit (Dako; Agilent Technologies, Inc) was used for ARID1A, SMARCA2, SMARCB1, SMARCC2, H3K27me3, CHD4, ACTL6A and p53 staining, and the EnVision Flex-kit (Dako; Agilent Technologies, Inc) was used for SMARCA4 staining to achieve better specificity, in accordance with the
manufacturer's instructions. Sections were dehydrated in an ethanol series (95, 99 and 100%) and cleared in xylene. Nuclear staining of stromal cells and vascular endothelium was used as a positive internal control and stroma was used as a negative internal control to evaluate the staining. In several cases, p53 immunostaining was performed to support histological diagnosis. The evaluation of IHC slides was conducted using a light microscope by two pathologists (NM and TI) who were blinded to the details of the patients.

**Immunohistochemical scoring.** The expression of ARID1A, SMARCA2, SMARCA4, SMARCBI, SMARCC2 and H3K27me3 was considered 'lost' when there was a complete absence of nuclear staining in tumor cells, while the surrounding normal cells exhibited consistently preserved nuclear staining. By contrast, ACTL6A, SMARCC2 and CHD4 expression were evaluated using an H-score, calculated by multiplying the proportion and intensity of tumor cells displaying nuclear staining. The proportion score was determined by assessing the percentage of tumor cells with positive nuclear staining relative to all tumor cells on the slide (0-100%). The intensity score was assessed using the intensity of the nuclear staining, categorized as follows: 0, not stained; 1, weak; 2, moderate; and 3, strong. The resulting H-score ranged from 0-300. The threshold value between the high and low protein expression groups was determined using the median H-score. Notably, stromal cells and vascular endothelium exhibited positivity and served as internal positive controls across all cases.

**Copy number assay.** Tumor DNA from each of the 203 cases was extracted from FFPE blocks using the DNAStorm FFPE Kit (Biotium, Inc.), according to the manufacturer's protocol. However, the copy number assay could not be conducted in some cases due to limited sample volume. Tumor DNA from each of the 203 cases was extracted from FFPE blocks using the DNAstorm FFPE Kit (Biotium, Inc.), according to the manufacturer's protocol. The relative quantities of DNA obtained from the PCR were analyzed using CopyCaller (Thermo Fisher Scientific Inc.) for CRF gene alterations (CNAs) were categorized as follows: Copy number <1, deep deletion; 1, shallow deletion; 2, diploid; 3-4, gain and >4, amplification.

**Statistical analysis.** All statistical analyses were performed using the JMP statistical software version 17 (SAS Institute, Inc.). The data were analyzed using Wilcoxon's rank-sum test. Multiple comparisons of DNA copy number data and immunohistochemical expression data were analyzed using the Wilcoxon rank-sum test with Bonferroni correction. For survival analysis, Kaplan-Meier analysis and the log-rank test were used. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Public data analysis.** The gene alterations of CRFs in ovarian serous carcinoma are summarized in Fig. 1A. Among 585 cases, 57% demonstrated CRF gene alterations, primarily in the form of gene amplification, which was observed in 208 (35.6%) cases. The most prevalent genetic alteration among CRFs in ovarian serous carcinoma was *ACTL6A* amplification (19.5%). However, this genetic alteration did not significantly affect OS (P=0.620; Fig. 1B). Patients with *SMARCC2* amplification (3.1%) had a significantly shorter median OS compared with patients with unaltered *SMARCC2* (P=0.005; Fig. 1C). Patients with *CHD4* amplification (5.7%) had a notably shorter OS compared with patients with unaltered *CHD4*; however, this association was not statistically significant (P=0.169; Fig. 1D). Furthermore, there was no significant association between *ACTL6A*, *SMARCC2* and *CHD4* mRNA expression levels and OS (Fig. S1A-C). However, *ACTL6A* mRNA expression was significantly higher in patients with *ACTL6A* amplification compared with in patients without alterations in the *ACTL6A* gene (P<0.001; Fig. S1D).

**Clinicopathological data analysis.** Table I presents the clinical characteristics of patients with OHGSC included in the present histological study. The age of the patients ranged from 28-87 years (mean, 58.3 years; median, 58 years). Out of the 203 cases, 148 (72.9%) had available 5-year clinical follow-up data, with a mean follow-up duration of 61.9 months (1-233 months). The majority of patients (78.4%) presented with advanced stage disease (III-IV). In total, there were 124 cases (61.1%) with recurrence, and 81 cases (39.9%) resulted in disease-related death.

Regarding treatment, all cases underwent surgical resection. Additionally, 195 cases (96.1%) received adjuvant chemotherapy, consisting of various regimens, such as paclitaxel and carboplatin, dacotaxel and carboplatin, cyclophosphamide, doxorubicin and cisplatin, cyclophosphamide, epirubicin and cisplatin, or paclitaxel and cisplatin. Furthermore, 9 cases received maintenance treatment, which supplemented chemotherapy with bevacizumab treatment.

**Immunohistochemical results.** Figs. 2, S2 and S3 display representative images of IHC staining, while the summarized IHC results are presented in Table II. ARID1A, SMARCA2, SMARCA4, SMARCBI, SMARCC2 and H3K27me3 were predominantly expressed in the nucleus of the tumor cells (Fig. S2). Nuclear staining of CRFs was lost in 8.9% of cases. Specifically, loss of nuclear ARID1A staining occurred in 2.5% of cases, SMARCA2 in 2.5% of cases and SMARCA4...
MAGARIFUCHI et al: DYSFUNCTION OF CHROMATIN REMODELING FACTORS IN OHGSC

in 3.9% of cases (Table II; Fig. 2A-C). Additionally, 2.5% of cases exhibited loss of H3K27me3 expression (Table II; Fig. 2D). The nuclear staining of these markers in stromal cells and vascular endothelium served as a positive internal control. Loss of ARID1A, SMARCA2 and SMARCA4 protein expression was mutually exclusive, and the loss of H3K27me3 was not related to loss of the protein expression of these CRFs. However, SMARCC2 and SMARCB1 protein expression was retained in all cases (Table II). The intensity of ACTL6A, SMARCC2 and CHD4 protein expression was higher in tumor cells compared with in stromal cells or lymphocytes (Fig. 2E-G). In addition, the nucleus of OHGSC tumor cells was strongly and diffusely positive for p53 (Fig. 2H).

The H-score of ACTL6A, SMARCC2 and CHD4 ranged from 140-220 (mean 169.66), 140-210 (mean 180.39), and 60-210 (mean 168.82), respectively. The median H-scores: 170 for ACTL6A, 180 for SMARCC2 and 170 for CHD4, were used as the cutoff values for distinguishing low and high CRF expression; representative images of high and low ACTL6A, SMARCC2 and CHD4 staining are shown (Fig. S3A-F).

Copy number analysis. Fig. 3A presents a summary of the DNA copy numbers of ACTL6A, SMARCC2 and CHD4 in OHGSC. Results were obtained for 154 cases for ACTL6A, 143 cases for SMARCC2 and 140 cases for CHD4, out of a total of 203 cases.
For comparison, normal skeletal muscle tissue was used as the control and the copy numbers were normalized to Rnase P, which served as the internal control. The copy numbers of ACTL6A, SMARCC2 and CHD4 ranged from 1‑8 (mean 3.09), 1‑7 (mean 2.27), and 0‑5 (mean 1.34), respectively. Notably, CNAs with increased copy numbers were predominant in ACTL6A and SMARCC2, while CHD4 CNAs primarily exhibited decreased copy numbers. Among the cases assessed, 102 out of 154 (66.2%) demonstrated ACTL6A copy number gain or gene amplification, 48 out of 143 (33.5%) showed SMARCC2 copy number gain or gene amplification, and 99 out of 140 (70.7%) demonstrated CHD4 shallow deletion or deep deletion. The relationship between ACTL6A, SMARCC2 and CHD4 copy numbers and the immunohistochemical expression of these proteins was assessed. However, no statistically significant association was observed between the copy numbers and the protein expression of ACTL6A (Fig. 3B), SMARCC2 (Fig. 3C) and CHD4 (Fig. 3D).

### Table I. Clinicopathological features of patients with OHGSC (n=203).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FIGO stage</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>21 (10.3)</td>
</tr>
<tr>
<td>II</td>
<td>23 (11.3)</td>
</tr>
<tr>
<td>III</td>
<td>114 (56.2)</td>
</tr>
<tr>
<td>IV</td>
<td>45 (22.2)</td>
</tr>
<tr>
<td>T stage</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>30 (14.8)</td>
</tr>
<tr>
<td>2</td>
<td>37 (18.2)</td>
</tr>
<tr>
<td>3</td>
<td>136 (67.0)</td>
</tr>
<tr>
<td>N stage</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>68 (33.5)</td>
</tr>
<tr>
<td>1</td>
<td>104 (51.2)</td>
</tr>
<tr>
<td>X</td>
<td>31 (15.3)</td>
</tr>
<tr>
<td>M stage</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>158 (77.8)</td>
</tr>
<tr>
<td>1</td>
<td>45 (22.2)</td>
</tr>
<tr>
<td>Recurrence</td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>79 (38.9)</td>
</tr>
<tr>
<td>+</td>
<td>124 (61.1)</td>
</tr>
<tr>
<td>Adjuvant chemotherapy</td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>8 (3.9)</td>
</tr>
<tr>
<td>+</td>
<td>195 (96.1)</td>
</tr>
<tr>
<td>Tumor-related mortality</td>
<td></td>
</tr>
<tr>
<td>NED</td>
<td>52 (25.6)</td>
</tr>
<tr>
<td>AWD</td>
<td>15 (7.4)</td>
</tr>
<tr>
<td>DOD</td>
<td>81 (39.9)</td>
</tr>
<tr>
<td>NA</td>
<td>55 (27.1)</td>
</tr>
</tbody>
</table>

NED, no evidence of disease; AWD, alive with disease; DOD, dead of disease; NA, not available; X, regional lymph node metastasis not evaluable.

### Table II. Immunohistochemistry results.

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Positivity</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARID1A</td>
<td>Lost</td>
<td>5/203 (2.5)</td>
</tr>
<tr>
<td></td>
<td>Retained</td>
<td>198/203 (97.5)</td>
</tr>
<tr>
<td>SMARCA2</td>
<td>Lost</td>
<td>5/203 (2.5)</td>
</tr>
<tr>
<td></td>
<td>Retained</td>
<td>198/203 (97.5)</td>
</tr>
<tr>
<td>SMARCA4</td>
<td>Lost</td>
<td>8/203 (3.9)</td>
</tr>
<tr>
<td></td>
<td>Retained</td>
<td>195/203 (96.1)</td>
</tr>
<tr>
<td>SMARCB1</td>
<td>Lost</td>
<td>0/203 (0)</td>
</tr>
<tr>
<td></td>
<td>Retained</td>
<td>203/203 (100)</td>
</tr>
<tr>
<td>SMARCC2</td>
<td>Lost</td>
<td>0/203 (0)</td>
</tr>
<tr>
<td></td>
<td>Retained</td>
<td>203/203 (100)</td>
</tr>
<tr>
<td>H3K27me3</td>
<td>Lost</td>
<td>5/203 (2.5)</td>
</tr>
<tr>
<td></td>
<td>Retained</td>
<td>198/203 (97.5)</td>
</tr>
</tbody>
</table>

ARID1A, AT‑rich interaction domain 1A; SMARC, SWI/SNF related, matrix associated, actin dependent regulator of chromatin; SMARCA, SMARC subfamily a; SMARCB, SMARC subfamily b; SMARCC, SMARC subfamily c; H3K27me3, tri‑methylation of lysine 27 of histone H3.

### Relationship between prognosis and CRFs.

The survival analyses for copy numbers of CRFs are summarized in Fig. S4, while the association of protein expression with OS is presented in Fig. 4.

Regarding the CNAs of ACTL6A, SMARCC2 and CHD4, changes in copy number of these genes demonstrated no statistically significant association with the OS of patients (P=0.434, P=0.629 and P=0.578, respectively; Fig. S4A‑C). Similarly, there was no significant association between the copy numbers of these CRFs and the FIGO stage (P=0.506, P=0.862 and P=0.974, respectively; Fig. S4D‑F). However, although not significant (P=0.094), in patients with FIGO stage III/IV OHGSC, copy number gain or amplification in either ACTL6A, SMARCC2 or CHD4 demonstrated unfavorable outcome trends compared with patients with diploid ACTL6A, SMARCC2 and CHD4 (Fig. S4G).

Moreover, although not significant (P=0.128), patients with FIGO stage III/IV with shallow or deep deletions in either ACTL6A, SMARCC2 or CHD4 demonstrated unfavorable outcome trends compared with those with ACTL6A, SMARCC2 and CHD4 diploids (Fig. S4H). However, due to the small number of cases, the effect of CRF CNAs on FIGO stage I/II cases could not be analyzed.

In cases with decreased protein levels of ARID1A, SMARCA2 or SMARCA4, similar outcome trends were demonstrated in OS compared with those with retained expression levels, and there was no statistically significant difference (P=0.879; Fig. 4A). Notably, patients with high ACTL6A protein levels demonstrated a statistically longer OS compared with patients with low ACTL6A protein levels (P=0.027; Fig. 4B).

Regarding the association with FIGO stage, higher SMARCC2 protein expression was detected in patients with a higher FIGO stage, but this relationship was not statistically significant (P=0.198; Fig. 4D). Likewise, the difference between ACTL6A and CHD4 protein levels and FIGO stage
was not found to be significantly different (P=0.315 and P=0.775, respectively; Fig. 4C and E).

**Discussion**

The present study conducted a comprehensive analysis of the relationship between CRF alterations and the clinicopathological features of OHGSC. The findings revealed CNAs in *ACTL6A*, *SMARCC2* and *CHD4* in OHGSC, as well as protein loss of *ARID1A* (2.5%), *SMARCA2* (2.5%) and *SMARCA4* (3.9%), indicating possible gene alterations. Notably, low protein expression levels of *ACTL6A* were identified as a positive indicator of shortened OS in patients with OHGSC.
Adenosine triphosphate (ATP)-dependent chromatin remodeling complexes regulate the chromatin packing state by sliding, ejecting and restructuring the nucleosome for transcriptional regulation (19). The Brg1-associated factor (BAF) complex is composed of a central ATPase (SMARCA2 or SMARCA4) and multiple BAFs, including ARID1A, ACTL6A and SMARCC2, which are assembled in a combinatorial fashion to dictate functional specificity (20). Overall, complex stoichiometry is influenced by individual BAFs that can regulate the expression of other subunits (21).

CHD4 is a core component of the nucleosome remodeling and deacetylase complex that combines chromatin remodeling activity with histone deacetylase and demethylase functions, which are involved in transcriptional repression (22). CHD4 comprises a core ATPase/helicase domain flanked by two plant homeodomain motifs that recognize modifications of histone tails, tandem chromodomains and carboxyl-terminal domains (23).

Previous studies have highlighted the amplification and upregulation of ACTL6A in numerous types of cancer, such as ovarian cancer, glioma, squamous cell carcinoma, osteosarcoma and hepatocellular carcinoma (24-28). ACTL6A has been implicated in promoting metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma (28) and colon cancer (29). Additionally, it has been reported to serve a role in tumorigenesis in head and neck squamous cell carcinoma (26) and glioma (25) by activating the Hippo/YAP pathway. In the context of ovarian cancer, high mRNA expression of ACTL6A has been reported to be associated with shortened OS (24) and platinum resistance (30). In the present study, public data demonstrated no significant association between ACTL6A mRNA expression and prognosis in patients with ovarian serous carcinoma; however, low ACTL6A protein expression levels, as detected by IHC, were associated with decreased OS. Thus, the protein levels and mRNA levels may not comparable. Differences between mRNA and protein levels may arise due to technical or biological reasons, such as post-transcriptional regulation (31). The process of mRNA stabilization needs to be elucidated to prove these divergences.

Figure 3. DNA copy number analysis of ACTL6A, SMARCC2 and CHD4 using the TaqMan copy number assay. (A) Copy numbers were primarily increased in ACTL6A and SMARCC2 and decreased in CHD4; these values were normalized to the internal control RNase P. A total of 66.2% of cases exhibited ACTL6A copy number gain or gene amplification, 33.5% demonstrated SMARCC2 copy number gain or gene amplification, and 70.7% displayed CHD4 deep deletion or shallow deletion. The relationship between (B) ACTL6A, (C) SMARCC2 and (D) CHD4 copy numbers and their immunohistochemical expression. No statistically significant association was demonstrated between the different copy numbers and protein expression. ACTL6A, actin-like protein 6A; SMARCC2, switch/sucrose non-fermentable related, matrix associated, actin dependent regulator of chromatin subfamily c member 2; CHD4, chromodomain-helicase-DNA-binding protein 4.
Additionally, despite a *ACTL6A* copy number gain or gene amplification in 66.2% of the cases tested, a statistically significant association between the copy number and protein levels of *ACTL6A* was not found. The different steps in the gene expression pathway each involve a complex process that confers regulatory control. Likewise, other epigenetic factors, such as microRNAs and ubiquitination, may have contributed to *ACTL6A* protein expression. Moreover, *ACTL6A* may affect the expression of oncogenes although *ACTL6A* mRNA expression was not related to prognosis. According to the present results, poor prognosis may be caused by the dysregulated transcription of other oncogenes or tumor suppressor genes following the decrease in *ACTL6A* protein expression. In vitro or in vivo analysis using protein knockdown or gene knockout of *ACTL6A* may be required to evaluate these hypotheses.

In the present study, it was demonstrated that patients with a higher FIGO stage tended to exhibit higher *SMARCC2* protein expression. Furthermore, the analysis of TCGA data demonstrated that patients with *SMARCC2* amplification had a shorter median OS compared with patients with wild-type *SMARCC2* in ovarian serous carcinoma. Several studies have indicated that *SMARCC2* is deficiently expressed in cancer (32,33). *SMARCC2* has been reported to inhibit tumor development by mediating the expression of the transcription factor early growth response 1 via chromatin remodeling, and by inhibiting activation of the phosphoinositide 3-kinase-AKT pathway in glioblastoma (33). However, several studies have reported *SMARCC2* gene amplification in cancer, such as follicular lymphoma (34) and hepatocellular carcinoma (35), in line with the results of the present study. These results collectively suggested that *SMARCC2* function varies according to tumor type, and that aberrant *SMARCC2* expression could be involved in the regulation of numerous cellular functions, such as cell proliferation and the cell cycle of the tumor.

Additionally, patients in FIGO stage III/IV who have copy number gain or amplification in either *ACTL6A*, *SMARCC2* or *CHD4* had a poor prognosis compared with those of wild-type *ACTL6A*, *SMARCC2* and *CHD4* diploids. In the present study, 8.9% of cases exhibited a deficiency in either ARID1A, SMARCA2 or SMARCA4 protein levels. Notably, the deficiency in ARID1A, SMARCA2 and
SMARCA4 was found to be mutually exclusive in this analysis. This exclusivity is attributed to the biochemical and functional heterogeneity of BAF complexes (36), and numerous epigenetic mechanisms are involved in the instability and silencing of SMARCA2, SMARCA4 and other subunits of the BAF complex (37). The BAF-chromatin remodeling complex, with its mutually exclusive ATPases SMARCA2 and SMARCA4, is essential for the transcriptional activation of numerous genes (38).

Furthermore, changes in nucleosome distribution pattern and density have been linked to reduced levels of H3K27me3 in chromatin remodeling enzyme mutants (39). However, in the present study, the loss of H3K27me3 was not found to be associated with the loss of CRFs expression.

The molecular biology of OHGSC is characterized by genomic complexity, often lacking targetable oncogenic alterations (40). Nonetheless, the present study revealed aberrant protein expression and CNAs of CRFs in OHGSC, which supports their potential use as therapeutic targets.

One limitation of the present study is the lack of in vivo confirmation of CRF expression in OHGSC. Thus, future studies using animal models are required to validate these findings.

There are ongoing developments in drugs that target genomic abnormalities of CRFs and combination therapies aimed at enhancing the therapeutic effects of anticancer drugs (41). In a previous study, the histone deacetylase inhibitor romiprosin, which targets CHD4, was demonstrated to suppress the progression of metastases in ovarian cancer both in vitro and in vivo (42). Additionally, panobinostat was reported to counteract ACTL6A-induced cisplatin resistance by inhibiting the repair of cisplatin-DNA adducts in vivo (30).

In conclusion, the present study demonstrated copy number and protein expression alterations of CRFs in OHGSC. Notably, the protein expression levels of ACTL6A were found to be associated with poor prognosis. These findings suggested that CRFs could be prognostic markers for OHGSC. However, further research is required to fully understand the mechanisms through which CRFs contribute to transcriptional aberration of oncogenes, particularly in the context of other epigenetic factors in OHGSC, and to investigate whether they are potential therapeutic targets for OHGSC.

Acknowledgements

The authors would like to thank Ms. Haruka Toki, Ms. Nahoko Ieiri, Ms. Jumi Yahiro, Ms. Motoko Tomita and Ms. Mami Nakamizo (Department of Anatomic Pathology, Kyushu University), for their technical support for this study.

Funding

This study received financial support from the ‘FUKUOKA’ OBGYN Researcher’s Charity Foundation Fund, Japan, through grants-in-aid.

Availability of data and materials

The data generated in the present study may be found in The Cancer Genome Atlas or at the following URL: https://www.cancer.gov/tcga. The other data generated in the present study may be requested from the corresponding author.

Authors’ contributions

NM and TI conducted the research and wrote the article. KK, YK, TT, MN and FN contributed to the sample collection and research design. YO designed the research and gave final approval of the article. NM, TI and YO confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was conducted in accordance with the principles of The Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Kyushu University (Fukuoka, Japan; approval nos. 21120-01, 21037-02 and 23005-00). There was an opt-out approach for consent where participants were informed of the trial on the homepage and were invited to opt-out if preferred.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


